Events

Courses

Examiners

Ph.D. Program

Application

Students

Past Students

Materials

FAQ

Home

Last update:
04.06.2012

Ph.D. Program > Examiners > Hannelore Ehrenreich

Hannelore Ehrenreich

Professor, Max-Planck-Institute for Experimental Medicine

1981 Doctor of veterinary medicine, University of Munich
1983 Elective Period, University of Newcastle-upon-Tyne, England
1985 Guest Lecturer, University of the Philippines, Manila
1985-1986 Assistant, Internal Medicine, University of Munich
1987 Graduation (Medicine), University of Munich
1987-1988 Assistant, Department of Neurology, University of Munich
1989 Doctor of Medicine, University of Munich
1989-1991 Guest (BMBF grant) NIAID, NIH, Bethesda, MD, USA
1992-1994 Assistant, Neurology and Psychiatry, University of Göttingen
1994 Habilitation (Neurology and Psychiatry)
1994-present Head, Division of Clinical Neuroscience, MPIEM
1995-present Consultant & Professor (1998) of Neurology & Psychiatry, University of Göttingen
2000-2002 Vice President, University of Göttingen

Major Research Interests:

Hannelore Ehrenreich

Translational Neuroscience
(1) Molecular-cellular basis of neuropsychiatric disease
with focus on endogenous mechanisms of neuroprotection
(2) Clinical research on neuroprotection and neuroregeneration
in acute (ischemia/hypoxia, trauma) and chronic brain disease (schizophrenia, autism, ALS, MS)
(3) Clinical addiction research

Novel concepts for treatment of alcoholism, psychotherapeutic process-outcome research including kinetics and mechanisms of regeneration

Address:
Max-Planck-Institute for Experimental Medicine
Dept. of Clinical Neurosciences
Hermann-Rein-Str. 3

37075 Göttingen
Germany

phone: +49-551-3899 615
fax: +49-551-3899 670
e-mail:

Further Information:
www.em.mpg.de

Selected Recent Publications:

Sirén, A.-L, Fratelli, M, Brines, M, Goemans, C, Casagrande, S, Lewczuk, P, Keenan, S, Gleiter, C., Pasquali, C, Capobianco, A, Mennini, T, Heumann, R, Cerami, A, Ehrenreich, H, Ghezzi, P: Erythropoietin prevents neuronal apoptosis after cerebral ischemia and in metabolic stress. Proc. Natl. Acad. Sci. USA 98: 4044-4049, 2001.

Ehrenreich, H, Degner, D, Meller, J, Brines, M, Béhé, M, Hasselblatt, M, Woldt, H, Falkai, M, Knerlich, F, Jacob, S,, Maier, W, Brück, W, Rüther, E, Cerami, A, Becker, W, Sirén, A-L:.Erythropoietin: A candidate for neuroprotection in schizophrenia. Mol Psychiatry 9: 42-54, 2004.

Ehrenreich H, Hasselblatt M, Knerlich F, von Ahsen N, Jacob S, Sperling S, Woldt H, Nave KA, Sirén AL: A hematopoietic growth factor, thrombopoietin, has a pro-apoptotic role in the brain. Proc. Natl. Acad. Sci. USA, 102: 862-7, 2005.

Sirén A-L, Radyushkin K, Boretius S, Kämmer D, Riechers C-C, Natt O, Sargin D, Watanabe T, Sperling S, Michaelis T, Price J, Meyer B, Frahm J and Ehrenreich H: Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin. Brain, 129: 480-489, 2006.

Ehrenreich H, Hinze-Selch D, Stawicki S, Knolle-Veentjer S, Aust C, Wilms S, Heinz G, Erdag S, Jahn H, Degner D, Ritzen M, Mohr A, Knauth M, Wagner M, Schneider U, Bohn M, Huber M, Czernik A, Pollmächer M, Maier W, Sirén A-L, Klosterkötter J, Falkai P, Rüther E, Aldenhoff JB, Krampe H: Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry, in press.